Regenxbio Analyst Price Targets - Benzinga

Regenxbio Inc

RGNXNASDAQ

Trade with Public

Trade with Public

$7.43

0.010.13%

마지막 업데이트: Oct 2, 7:24 PM

$7.48

0.060.81%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 주식 보고서

Regenxbio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Regenxbio (RGNX).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

9Buy

2Hold

Consensus RatingOutperform# Analysts11Avg. Consensus PT$24Upside to Avg. PT+218.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 25, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$23→$21
Aug 25, 2026	Baird	Brian Skorney	PT Cut	Outperform	$32→$29
Aug 10, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$26→$23
Aug 7, 2026	Barclays	Eliana Merle	Downgrade	Overweight→Equal-Weight	$12
Jun 24, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$26
Jun 22, 2026	Baird	Brian Skorney	PT Raise	Outperform	$27→$32
Jun 22, 2026	Leerink Partners	Mani Foroohar	PT Raise	Outperform	$17→$18
Jun 5, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$30→$26
May 15, 2026	B of A Securities	Geoff Meacham	PT Cut	Buy	$25→$14
May 15, 2026	Barclays	Gena Wang	PT Cut	Overweight	$37→$12
Mar 9, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$32→$30
Mar 6, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$18→$17
Feb 10, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$34→$32
Feb 10, 2026	Goldman Sachs	Paul Choi	PT Cut	Neutral	$14→$12
Feb 10, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$25→$18
Feb 10, 2026	Chardan Capital	Daniil Gataulin	PT Cut	Buy	$52→$50
Jan 29, 2026	Chardan Capital	Daniil Gataulin	Maintained	Buy	$52
Dec 19, 2025	Stifel	Annabel Samimy	PT Raise	Buy	$40→$45
Dec 15, 2025	Leerink Partners	Mani Foroohar	PT Raise	Outperform	$16→$20
Nov 20, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$52

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $21

HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $23 to $21.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Regenxbio, Lowers Price Target to $29

Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $32 to $29.

Benzinga Newsdesk

This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $23

HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $26 to $23.

Benzinga Newsdesk

This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday

Wall Street analysts changed outlook on top names. For rating changes, check our analyst ratings page. See analysts' views on ADIG, TSEM and more

Avi Kapoor

This HubSpot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Top Wall Street analysts changed outlook on top names. For all changes & stock ratings, see analyst ratings page. Some stocks downgraded & price targets lowered.

Avi Kapoor